CytoMed Therapeutics Limited
GDTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $39,235 | $52,089 | $31,660 | $27,739 |
| - Cash | $3,639 | $6,816 | $1,179 | $1,863 |
| + Debt | $339 | $339 | $3,150 | $2,416 |
| Enterprise Value | $35,935 | $45,612 | $33,631 | $28,292 |
| Revenue | $52 | $291 | $0 | $84 |
| % Growth | -82.1% | – | -100% | – |
| Gross Profit | $52 | $382 | -$81 | $82 |
| % Margin | 100.7% | 131.4% | – | 96.9% |
| EBITDA | -$1,791 | -$2,938 | -$1,095 | -$1,048 |
| % Margin | -3,443% | -1,011.1% | – | -1,244.7% |
| Net Income | -$1,883 | -$3,132 | -$2,271 | -$1,534 |
| % Margin | -3,621.1% | -1,077.8% | – | -1,822.3% |
| EPS Diluted | -0.16 | -0.29 | -0.3 | -0.22 |
| % Growth | 44.8% | 3.3% | -36.4% | – |
| Operating Cash Flow | -$1,984 | -$2,676 | -$1,044 | -$1,270 |
| Capital Expenditures | -$1,025 | -$44 | -$354 | -$432 |
| Free Cash Flow | -$3,010 | -$2,720 | -$1,398 | -$1,702 |